Vol.22, No.2, 2020, pp.95-105, doi:10.32604/oncologie.2020.012439
OPEN ACCESS
ARTICLE
Clinical Significance of CA-199 and LINC01197 in Pancreatic Cancer
  • Dan Zhang1, Shengyong Fu2,*, Jie Xu3, Xia Sun1
1 Department of Endocrinology, Lishui Municipal Central Hospital, Lishui, China
2 Department of Comprehensive Laboratory, Lishui International Travel Healthcare Center, Lishui, China 3 Department of Anorectal, Lishui Municipal Central Hospital, Lishui, China
* Corresponding Author: Shengyong Fu. Email: Shengyongfu@163.com
Abstract
This study aimed to explore the expression and clinical significance of LINC01197 in the serum of patients with pancreatic cancer (PC). Methods: A total of 50 PC patients (patient group) treated in our hospital from March 2012 to April 2014 were collected, and another 50 healthy people (normal group) were collected for physical examination. The expression of LINC01197 in the serum of the two groups was detected by qRT-PCR method, and the expression of CA-199 in serum was detected by Roche automatic biochemistry. The expression and diagnostic values of CA-199 and LINC01197 in PC were analyzed, and the relationship between LINC01197 and the prognosis of PC patients was observed. Results: The expression of CA-199 in the patient group was significantly higher than in the normal group (p < 0.001). The area under the curve was 0.791 and 0.944, respectively. The incidence rate of Phases III + IV, lymphatic invasion, and distant metastasis in patients with low expression of LINC01197 is significantly higher than that in patients with high expression and has higher diagnostic value. With the progress of clinical staging, the expression of TNM gradually decreased and there were differences between groups (p < 0.001). Sperman test analysis found that the decreased TNM staging of LINC01197 gradually increased (r = – 0.816, p < 0.001), and the area under the curve of LINC01197 distinguishing phase I and phase II + phase III + phase IV was 0.930. The 1-year survival rate and 5- year survival rate of patients in low expression group are lower than those in the high expression group (P1 year = 0.037, P5 year = 0.014). Distant metastasis is an independent prognostic factor for PC patients to survive for 1 to 5 years. Differentiation, TNM staging, and LINC01197 are independent prognostic factors for PC patients to survive for 5 years. Conclusion: The low expression of LINC01197 in PC patients indicates poor prognosis of patients and is expected to be a potential diagnostic and prognostic indicator of PC.
Keywords
LINC01197; pancreatic cancer; prognosis; diagnosis
Cite This Article
Zhang, D., Fu, S., Xu, J., Sun, X. (2020). Clinical Significance of CA-199 and LINC01197 in Pancreatic Cancer. Oncologie, 22(2), 95–105.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.